Flo Health has confirmed it has reached a settlement agreement in a class action lawsuit concerning data privacy allegations, with the company emphasizing that the settlement includes no admission of wrongdoing. The resolution comes after a federal judge expressed skepticism about the strength of the plaintiffs’ case, describing evidentiary issues as an “insurmountable” problem.
The settlement resolves claims that began in 2021, when users filed suit alleging that the period-tracking app shared sensitive health information with Meta without proper consent. The case attracted significant attention in the digital health privacy space, with extensive coverage of the proceedings highlighting the broader implications for health app privacy practices.
Flo Health, which serves over 420 million users worldwide as the #1 women’s health app, maintained throughout the proceedings that the allegations lacked merit. The company’s position appeared to be vindicated as the case progressed, with the presiding judge ultimately indicating he would dismiss the plaintiffs’ claims due to insufficient evidence.
“We have always maintained that the claims lacked merit, and as the case progressed, the lack of evidence to support these allegations became increasingly clear in Court,” a Flo Health spokesperson said. “Importantly, this settlement includes no admission of wrongdoing. We can now put the matter behind us so we can continue to focus on serving our customers and delivering our mission to advance the future of women’s health.”
The lawsuit stemmed from allegations that Flo Health shared users’ menstrual cycle data, including period dates and lengths, with Meta for advertising purposes without explicit user consent. However, both Flo Health and Meta consistently denied these claims throughout the legal proceedings.
The case originally involved five named claimants who argued they never provided permission for their sensitive health data to be shared with third parties. The lawsuit gained momentum following an earlier settlement between Flo Health and the Federal Trade Commission, though the company’s business profile shows continued strong growth and investor confidence.
Flo Health became Europe’s first femtech unicorn in July 2024 following a $200 million investment from General Atlantic, demonstrating continued market confidence in the company’s business model and privacy practices. The platform serves 76 million monthly active users and maintains its position as the #1 OB-GYN-recommended app for period and cycle tracking.
The settlement terms remain subject to final court approval, with additional details about the agreement and next steps for class members expected to be communicated through official court-approved channels in the coming weeks. The resolution allows Flo Health to move forward without the distraction of ongoing litigation.
Throughout the legal proceedings, Flo Health emphasized its commitment to user privacy and data protection. The company states it has never and will never sell user data, maintaining what it describes as rigorous, measurable, and independently verified privacy protections.
The timing of the settlement allows Flo Health to focus on recent product innovations, including the launch of comprehensive perimenopause support features that address a significant gap in women’s health care. The company continues to engage with its user community through social media platforms and other channels.
Flo Health’s privacy practices include award-winning features such as Anonymous Mode, which was recognized as one of TIME’s Best Inventions 2023. The company has also been named a finalist for Fast Company’s World Changing Ideas Awards, reflecting its commitment to privacy innovation in the digital health space.
The resolution of this legal matter enables Flo Health to continue its mission of supporting women at every stage of their health journey, from menstruation to conception, pregnancy, and menopause, while maintaining its focus on privacy leadership in the femtech sector.